Further investigation of the proliferative capacities using in vivo subcutaneous injections demonstrated that CdGAP-depleted tumors exhibited delayed tumor onset, reduced tumor volume, and tumor weight, in comparison to control tumors and this further substantiated the results obtained from the in vitro experiments. This evidence concerns the gene ARHGAP31 and neoplasm.